Rayzebio company information, Employees & Contact Information

RayzeBio’s new hub revolutionizes cancer treatment with next-gen RPTs Bristol Myers Squibb

BMS expands radiopharma pipeline via RayzeBio's $1.3B prostate cancer drug deal Fierce Biotech

BMS-owned RayzeBio licenses Philochem asset for $350 million up front Chemical & Engineering News

BMS, RayzeBio launch radiopharmaceutical manufacturing site in Indianapolis Fierce Pharma

Philochem AG Announces the Licensing of Worldwide Rights to OncoACP3, a novel Radiopharmaceutical Therapeutic and Diagnostic Agent targeting Prostate Cancer, to RayzeBio, a Bristol-Myers Squibb Company, for a potential value of up to $1.35bn plus r GlobeNewswire

RayzeBio, Inc. Announces Pricing of Upsized $311 Million Initial Public Offering Business Wire

RayzeBio drew other pharma interest before Bristol Myers deal BioPharma Dive

Telix heads to the US, as RayzeBio runs into problems | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

RayzeBio raises $160m to advance cancer radiopharmaceuticals Pharmaceutical Technology

BMS's RayzeBio unit opens $160M radiopharma plant in Indianapolis FirstWord Pharma

RayzeBio, Dice alums raise $370 million for new autoimmune startup statnews.com

RayzeBio Reports Third Quarter 2023 Financial Results and Provides Corporate Update Yahoo Finance

Bristol-Myers Squibb to Buy RayzeBio for $4.1 Billion The Wall Street Journal

Bristol Myers to buy RayzeBio for $4.1 billion in targeted cancer therapy push Reuters

RayzeBio, Inc. Announces Closing of Upsized $358 Million Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares Business Wire

Bristol Myers Squibb Adds Premier Radiopharmaceutical Platform with Acquisition of RayzeBio GlobeNewswire

Bristol Myers will pay $4.1 billion for cancer startup RayzeBio statnews.com

BMS enters radiopharma race with $4.1B acquisition of RayzeBio just 3 months after biotech went public Fierce Biotech

Bristol Myers Squibb agrees to acquire RPT company RayzeBio for $4.1bn Pharmaceutical Technology

RayzeBio to Present at the 41st Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2023 Business Wire

Bristol Myers Squibb acquires RayzeBio for $4.1bn Pharmaceutical Technology

Rx Rundown: BioNTech, Merck, RayzeBio and more Medical Marketing and Media

Bristol Myers' RayzeBio halts radiotherapy trial enrollment after isotope runs scarce Fierce Pharma

RayzeBio overshoots expectations with $311M IPO while Neumora hits $250M target Fierce Biotech

BMS won out against other pharmas in bid for RayzeBio, just days after competing for Karuna Fierce Biotech

New RayzeBio hub promises to deliver radiopharmaceutical therapies in three days The Pharma Letter

Radiopharmaceutical drugmaker RayzeBio signals plans to go public BioPharma Dive

Philochem Licenses OncoACP3 Worldwide Rights to RayzeBio Contract Pharma

Nimble Therapeutics and RayzeBio Announce Strategic Research Collaboration to Discover & Develop Novel Peptide-Based Radiopharmaceuticals Business Wire

RayzeBio Takes Short Trip From IPO to Buyout Barron's

RayzeBio Completes Phase 1b Enrollment in ACTION-1 Study, Evaluating RYZ101 (Actinium-225 DOTATATE) in Neuroendocrine Tumors Imaging Technology News

RayzeBio plans IPO to push radiotherapy 'pipeline-in-a-product' through phase 3 Fierce Biotech

Bristol Myers' $4.1 Billion Deal For RayzeBio Sends RYZB Stock Soaring 100% Investor's Business Daily

BMS, RayzeBio halt radiotherapy trial due to isotope shortage TechTarget

RayzeBio wants to give radiation therapy new life, and $108M should help Fierce Biotech

RayzeBio Inc. to be acquired by drugmaker Bristol Myers Squibb for $4.1B Indianapolis Business Journal

Money on the Move: Sparing Vision, RayzeBio, Nimbus and More Garner Funds BioSpace

Bristol Myers Squibb to acquire radiopharmaceutical specialist RayzeBio for $4.1bn PMLiVE

Markets - Medicine Hat News FinancialContent

RayzeBio-Partnered Startup Focused on Bringing Radiopharmaceuticals to China BioSpace